A clinical trial using vonoprazan to eradicate helicobacter pylori

The use of vonoprazan in eradicating helicobacter pylori: a single center randomized controlled study of noninferiority

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034722

Enrollment

Unknown

Registered

2020-07-16

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

helicobacter pylori infection

Interventions

A:Vonoprazan (20mg bid) + Amoxicillin (1g bid)

B:Vonoprazan (20mg qd) + Amoxicillin (1g bid)

C:Vonoprazan (20mg qd) + Amoxicillin (1g bid) + Jinghua Weikang

D:Esomeprazole (20mg bid) + Amoxicillin (1g bid) + Furazolidone (0.1g bid) +Livzon Dele (220mg bid), for 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with gastritis by endoscopy; 2. Aged older than 18 years; 3. Positive result after 13C or 14C test; 4. No previous treatment for Hp; 5. Signed the constent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Allergic to the drugs; 3. Have taken the PPIs, NSAIDs in the past two weeks; 4. With mental disease; 5. With severe organic disease.

Design outcomes

Primary

Measure	Time frame
Hp infection status;	—

Countries

China

Contacts

Public ContactHe Song

The Second Affiliated Hospital of Chongqing Medical University

hedoctor65@sina.com+86 13808336120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026